Add To Watchlist
Share URL
About The Company
Description
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally.
Read More
Overview
Value
2
Growth
61
Health
65
Management
79
Analyst Opinion
69
Total
55
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Has a low level of debt
- Has strong financial health
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Earnings growth has slowed down recently
- Income is not covering expenditure and investment
- There is a history of diluting shareholders
- No margin of safety at their current market price
Market Peers
OXB.L
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-99.45%
Revenue Growth (5 Year Average)
21.94%
Ratings Consensus
Buy
Share Buybacks
-17.18%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
2
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 428 GBp
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-0.05%
PE/Earnings Growth
N/A
Price/Book
15845.72x
Growth
Growth Score
61
- ✔ 5 Year Average Revenue growth of 21.94% is higher than the market average (10.97%)
- ✘ Revenue growth has slowed this year
- ✘ 5 Year Average Earnings growth of 12.25% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 12.25% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
21.94%
Earnings Growth
12.25%
Cashflow Growth
12.25%
Health
Health Score
65
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
0.05x
Current Assets/Liabilities
4.92x
Free Cashflow/Total Debt
1.71x
Debt/Capital
0.06x
Management
Management Score
79
Average Buybacks/Dilution
-17.18%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
31.89%
Return On Assets
735.41%
Return On Capital Employed
16.88%
Return On Equity
931.26%
Return On Free Cashflow
-17033.88%
Return On Investments
N/A
Analysts
Analyst Opinion
69
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Oxford Biomedica plc
Currency
GBp
Beta
1.031764
Vol Avg
153807
Ceo
Mr. John Dawson
Cik
Cusip
G6836F189
Exchange
London Stock Exchange
Full Time Employees
959
Industry
Biotechnology
Sector
Healthcare
Ipo Date
1996-11-15
Address
Windrush Court, Transport Way
City
Oxford
State
OXFORDSHIRE
Country
GB
Zip
OX4 6LT
Phone
441865783000
All financial data provided by FMP